ArticleScience translational medicine2020
Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling.
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 95 citations in OpenAlex.
- Multimodal profiling of pro-inflammatory protease activity identifies caspase-1 as a target for lung cancer interception.Science advances · 2026Article
- Proteolysis activity mapping and substrate discovery platform for identifying tumor-activated biosensors.Nature chemical biology · 2026Article
- Urinary detection of therapy-induced senescence and fibrosis using an injectable albumin-based nanoprobe.Nature aging · 2026Article
- Article
- Deep learning guided design of protease substrates.Nature communications · 2026Article
- Artificially Engineered Synthetic Biomarkers Revolutionizing Early Diagnosis of Diseases.Molecules (Basel, Switzerland) · 2025Review
- Machine learning-based characterization of a PANoptosis-associated model for enhancing prognosis and immunotherapy response in lung adenocarcinoma patients.Discover oncology · 2025Article
- An enzymatic cleavage-triggered minimally invasive nanosensor for urine-based detection of early atherosclerosis.Science advances · 2025Article
- The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection.Exploration of targeted anti-tumor therapy · 2025Review
- A tumor-infiltrating B lymphocytes -related index based on machine-learning predicts prognosis and immunotherapy response in lung adenocarcinoma.Frontiers in immunology · 2025Article
- Profiling protease cleavage patterns in plasma for pancreatic cancer detection.Scientific reports · 2024Article
- A breath-based in vitro diagnostic assay for the detection of lower respiratory tract infections.PNAS nexus · 2024Article
- Biomarkers in Cancer Screening: Promises and Challenges in Cancer Early Detection.Hematology/oncology clinics of North America · 2024Review
- Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Description of an activity-based enzyme biosensor for lung cancer detection.Communications medicine · 2024Article
- Inhalable point-of-care urinary diagnostic platform.Science advances · 2024Article
- CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics.Journal of visualized experiments : JoVE · 2023Article
- The Importance of Animal Models in Biomedical Research: Current Insights and Applications.Animals : an open access journal from MDPI · 2023Review
- Embracing enzyme promiscuity with activity-based compressed biosensing.Cell reports methods · 2023Article
- Profile of Sangeeta Bhatia.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
- Commented on byCatching cancer.2020
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
Lung cancer is the leading cause of cancer-related death, and patients most commonly present with incurable advanced-stage disease. U.S. national guidelines recommend screening for high-risk patients with low-dose computed tomography, but this approach has limitations including high false-positive rates. Activity-based nanosensors can detect dysregulated proteases in vivo and release a reporter to provide a urinary readout of disease activity. Here, we demonstrate the translational potential of activity-based nanosensors for lung cancer by coupling nanosensor multiplexing with intrapulmonary delivery and machine learning to detect localized disease in two immunocompetent genetically engineered mouse models. The design of our multiplexed panel of sensors was informed by comparative transcriptomic analysis of human and mouse lung adenocarcinoma datasets and in vitro cleavage assays with recombinant candidate proteases. Intrapulmonary administration of the nanosensors to a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.